MedPath

A controlled, Randomised, Parallel, Multicentre Study to Assess Safety and Tolerabillity of the Oral Direct Thrombin Inhibitor AZD0837 in the Prevention of Stroke and other Thromboemboelic Complications. Associated with Atrial Fibrillatio

Conditions
Prevention of stroke and other thromboembolic omplications associated with Artrial Fibrillation.
Registration Number
EUCTR2004-000359-41-DK
Lead Sponsor
AstraZeneca AB
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
270
Inclusion Criteria

Are the trial subjects under 18?
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath